NICE unlocks use of Amarin's Vazkepa in 425k NHS patients

Health technology assessment (HTA) agency NICE has finalised its guidance on Amarin's Vazkepa, clearing the path for GPs to start prescribing the drug in up to 425,000 NHS patients at high

NICE backs NHS use of Amarin's Vazkepa for cardiovascular ri...

Around 425,000 people in England and Wales with cardiovascular disease who are at risk of a secondary stroke or heart attack, could be eligible for treatment with Amarin's Vazkepa, followin

Is cardiovascular disease a ‘pandemic hiding in plain sight’...

Amarin’s Craig Granowitz discusses the impact of COVID on cardiovascular disease treatment and explains why there’s still a long way to go till we can truly tackle these diseases.<

UK regulator backs Amarin's cardiology drug Vazkepa

Amarin’s Vazkepa cardiology drug has been backed by the UK’s drugs regulator, following approval in Europe at the end of March. 

Amarin hit hard as generics loom for fish oil drug Vascepa

Amarin gets FDA panel okay for new Vascepa indication